Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cygnus GlucoWatch Pilot Marketing Program To Begin In April

This article was originally published in The Gray Sheet

Executive Summary

Cygnus plans to kick off a pilot marketing program in April targeting 100-150 Type 1 diabetes patients to gauge firsthand consumer experience with the GlucoWatch Biographer. The non-invasive glucose monitoring system was approved by FDA on March 22.

You may also be interested in...



Cygnus GlucoWatch Biographer Non-Invasive Glucose Monitor Lists For $595

Cygnus' full-scale U.S. launch of the GlucoWatch Biographer non-invasive glucose monitoring system April 15 includes a direct mail list price of $595

Cygnus GlucoWatch Biographer Non-Invasive Glucose Monitor Lists For $595

Cygnus' full-scale U.S. launch of the GlucoWatch Biographer non-invasive glucose monitoring system April 15 includes a direct mail list price of $595

Cygnus GlucoWatch

Non-invasive glucose monitoring system indication for use by diabetics ages 7-17 is sought in a PMA supplement submission, announced Sept. 24. The device was approved for adults 18 and older on March 22 (1"The Gray Sheet" March 26, 2001, p. 13). About 100,000 children and 16 mil. adults have diabetes in the U.S. While the wristwatch-like device is currently available under a pilot marketing program, Cygnus is preparing for a full-scale launch and reports to be "in advanced discussions with multiple companies for a potential sales alliance in the U.S."

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel